Navigation Links
Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy
Date:7/14/2014

Hicksville and Hauppauge, NY (PRWEB) July 14, 2014

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Ozurdex, a corticosteroid manufactured by Allergan, recently obtained an additional FDA-approved indication for use in diabetic macular edema. Ozurdex was previously approved by the FDA in 2009 for treatment of retinal vascular occlusions and and in 2010 for non-infectious uveitis (inflammation in the eye).

DME, a leading cause of vision loss in diabetic patients, is a condition in which microvascular damage from diabetes leads to leakage in the central portion of the retina, the macula. This causes blurring and loss of vision, and eventually legal blindness. The OZURDEX® biodegradable implant is delivered as an injection, and is administered during an office visit. The medication is slowly released over a period of months, suppressing inflammation, a key factor in DME. On average, patients receiving the medication demonstrate an improvement in vision and less leakage.

According to James M. Maisel, M.D., Chairman of the Retina Group of New York and a vitreoretinal surgeon, “Laser treatments and vitreous surgery have nearly eliminated the blinding complications of proliferative diabetic retinopathy for decades. However, over half a million diabetics with the background form of diabetic retinopathy develop diabetic macular edema (DME), threatening their fine vision, and their ability to read and drive. Precise focal laser treatment for DME typically only slowed visual loss. In 2010, Lucentis® was approved for treatment of DME and quickly became the standard of care, stabilizing or improving vision two lines in two years in about 1/3 of patients but often requiring monthly injections. We are thrilled to now have a secon
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
3. New type of retinal prosthesis could better restore sight to blind, Stanford study says
4. Prosthetic retina offers simple solution to restoring sight
5. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
6. Retinal Device Restores Sight to Blind Mice
7. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
8. UCIs Gavin Herbert Eye Institute receives $3 million for retinal degeneration research
9. San Antonio Eye Center Welcomes Retina Specialist Dr. Calvin Christopher Brown
10. Nationally-Recognized Retinal Expert Returns to Gainesville, Joins Retina Specialty Institute
11. Preferred retinal location may aid rehabilitation in patients with central vision loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... -- A leading group of oncologists has released updated ... advanced breast cancer. HER2-negative breast tumors include ... HER2 protein, the American Society of Clinical Oncology (ASCO) ... 80 percent of women with advanced breast cancer have ... guideline, our aim is to improve both the length ...
(Date:9/2/2014)... latest research on sleep apnea, tonsillectomies, hearing loss, ... will be presented in Orlando, FL, September 21-24, ... of the American Academy of OtolaryngologyHead and Neck ... ear, nose, throat, head and neck physicians in ... be presented were released today, and are available ...
(Date:9/2/2014)... September 02, 2014 The first ... Pinnacle hip implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon ... the U.S. District Court, Northern District of Texas, ... Johnson & Johnson and its DePuy Orthopaedics unit ... all-metal hip caused recipients to suffer serious and ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... leverage Risk MonitorPro, (R) and Feedback ... patient feedback and adverse events,CAMBRIDGE, MA, Jan. 13 ... quality and safety software, announced today that Woman,s Hospital ... and quality of care initiatives. , Named by Modern ...
... Straight Wire Seminars(TM) Celebrates 3 Decades of Orthodontic ... Straight Wire Seminars , Inc., a leading provider ... 30th anniversary starting this month, January 2009. ... milestone by offering a wide array of courses ...
... to enter Animal Health Rapid Diagnostics Market with a ... 13 Abaxis, Inc. (Nasdaq: ABAX ), ... for both the medical and veterinary markets, announced today ... for the manufacturing of a Canine Heartworm Lateral Flow ...
... Merck Serono and Apitope to Collaborate on Development ... the Treatment of Multiple Sclerosis (MS)GENEVA, Jan. 13 ... Darmstadt, Germany, announced today the signature of a ... (Bristol) Ltd., a wholly owned subsidiary of Apitope ...
... The National Eczema Association (NEA) awarded its Seal ... Theraplex Clear Lotion .The NEA Seal of Acceptance is ... program, which is intended to improve the quality of ... skin. "These products met our criteria for having no ...
... and Web 2.0 as Top Security Concerns and Steps Organizations Need to ... ... Ariz. (PRWEB) January 13, 2009 -- What will be the biggest threats ... 24 months? Cybercrime, data breaches , Web 2.0 and outsourcing were ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:Don't Trust Any Continuing Education Provider Under 30 2Health News:Don't Trust Any Continuing Education Provider Under 30 3Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 2Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 3
(Date:9/2/2014)... -- Reportlinker.com announces that a new market research report is ... Taiwanese Markets for Minimally Invasive Spinal Devices ... market for MIS spinal devices in the ... a fast pace, albeit at different rates in different ... China , where MIS spinal fusion is ...
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... 2014 According to a ... "Latin America Home Healthcare Market (By Device Types: ... Mobility Assist Devices and Medical Supplies; By Services: ... and Unskilled Home Healthcare Services) - Industry Analysis, ... 2020" the Latin American Home Healthcare market was ...
Breaking Medicine Technology:Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6
... announced today that Apligraf®, the only product with FDA ... and venous leg ulcers, will have two new procedure ... Services (CMS) as of January 2011. The new codes ... application of Apligraf in accordance with its FDA labeling ...
... 10, 2010 Filtrona Porous Technologies, a custom ... fiber components designed to absorb, retain, transfer, filter ... expanded range of polyurethane foams and bonded fibers ... Dusseldorf, Germany from 17 to 19 November 2010. ...
Cached Medicine Technology:Apligraf Reimbursement to Benefit from New CMS Codes 2
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: